Gene expression of aged skin more closely resemble young skin with the use of Sciton BroadBand Light treatment
Led by dermatologist Dr. Anne Lynn S. Chang of the Stanford University School of Medicine, the study (“Rejuvenation of Gene Expression Pattern of Aged Human Skin by BroadBand Light Treatment”) reveals the molecular changes that are induced by BBL, a popular treatment made by Sciton for improving the appearance of acne, sun spots, freckles and vascular conditions. BBL treatments are requested by patients for promoting a more youthful and rejuvenated appearance. Previous studies have shown that animal models can exhibit gene expression changes to become more youthful. Dr. Chang’s study is the first to show a similar correlation in human skin treated with BBL.
“As an industry, to find a clinically sound solution for human anti-aging is critical,” said Dr. Macrene Alexiades-Armenakas, board certified dermatologist, attending physician at Lenox Hill Hospital and Yale/New Haven VA Hospital, and Assistant Clinical Professor at Yale University School of Medicine. “As a practicing physician in the field of dermatology, it is exciting to know there is a safe, light based treatment with groundbreaking clinical evidence supporting anti-aging and the reversal of skin damage available to our patients.”
An additional study, submitted for publication by Dr. Patrick H. Bitter, Jr. of Advanced Aesthetic Dermatology, a well-known dermatologist and co-author of the JID study, takes this groundbreaking research further and explores the practical application and patient results of BBL treatments. Dr. Bitter’s study focuses on the ability to improve the appearance of aging skin with long-term and regular interval treatments with BBL.
“The JID study is an important first step to prove that BBL treatments are a viable option for anti-aging,” said Dr. Bitter. “In my upcoming study, we provide clinical evidence on patients who have had BBL and have enjoyed younger looking skin over the long-term. I look forward to sharing these demonstrated results with my colleagues and patients worldwide in the near future.”
“As the developer of the BBL technology, Sciton remains committed to investments not only in the equipment but in the science required to inform the development of meaningful applications for it. The BBL has an unsurpassed reputation for delivering clinically important results,” said Sciton co-founder and President, Dan Negus, Ph.D. “These basic science and clinical biomedical studies demonstrate another important validation for the dermatologic community of the sound scientific basis of the BBL technology and the results it produces.”
The study’s additional authors are Dr. Howard Y. Chang and Nicole A. Rapicavoli, both of Howard Hughes Medical Institute and Stanford University, and Dr. Kun Qu and Dr. Meihong Lin, both of Stanford University. To read the full text of the study, please visit.
Sciton is committed to providing best-in-class laser and light source solutions for medical professionals who want exceptional durability, performance and value. Sciton offers superior medical devices for fractional and full-coverage skin resurfacing, superficial and deep skin peeling, hair removal, phototherapy, wrinkle reduction, laser-assisted lipolysis, treatment of vascular and pigmented lesions and varicose veins, nail fungus, scar reduction and acne treatment. For more information and a complete listing of Sciton systems, visit www.sciton.com.
About BroadBand Light (BBL) Treatment:
With its user-friendly features, superior results, and exceptional ROI, BBL™ is the most complete and versatile broadband light system in its class. Its broad range of wavelengths allow targeted treatment for many skin conditions including acne, pigmented lesions, vascular lesions and hair removal. For more information, please visit www.ForeverYoungBBL.com.
*BBL is not FDA cleared for changing gene expression or anti-aging.